Nine Months Ended
$996,586Cost of sales
594,266Operating expenses:Selling, general and administrative
296,712Research and development
81,822Amortization of acquired intangible assets
11,055Total operating expenses'/>"/>
SOURCE ResMed Inc.
Copyright©2012 PR Newswire.
All rights reserved
Related medicine technology :
1. ResMed Noninvasive Ventilation Device Cleared by FDA for COPD Treatment
2. ResMed Announces Conference Call And Webcast To Discuss Third Quarter 2013 Results
3. ResMed Takes Action to Enforce Patents
4. Buoyed by Forecasts, Where 2013 Leads - Research Report on ResMed Inc., Zimmer Holdings, Inc., Waters Corporation, Covidien PLC, and Medtronic, Inc.
5. ResMed Inc. Announces Record Financial Results For The Quarter Ended And Six Months Ended December 31, 2012
6. ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
7. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2012
8. ResMed Inc. Announces Record Financial Results For The Quarter And Twelve Months Ended June 30, 2012
9. ResMed Announces Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year-End 2012 Results
10. ResMed Launches Narval™ CC Mandibular Repositioning Device in the US
11. ResMed Inc. Announces Plan To Initiate Dividend And Update On Chief Executive Officer Succession